

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EVO				RECO	
1 2 2003	,		7	ECH FEB 14 VED	
IN TH	E UNITED STATES PA	TENT AND TRADI	EMARK OFFICE	CENTER 1003	
In re application of: Serial No.: Filing Date: For: Docket No.	Wagle, et al. 09/905,035 July 13, 2001 Cyanomethyl Substitut Disorders Associated v 361331-505	ted Thiazolium and I	: Stockton, Laura I	• / / /	
Commissioner for Patents Washington, DC 20231					
the United States P Commissioner for	t this correspondence is boostal Service as first-class Patents, Washington, D.C. By: AATION DISCLOSUR	s mail in an envelope 2. 20231, on February Peggy Ferello	addressed to: 6, 2003. 4 Ferells		
	cants herein make availa				
Ø	listed on enclosed For accordance with 37 CF	•	ormerly PTO-1449	9), in	
	listed on enclosed copin PTO/SB/08A/B, which applications to which the 35 U.S.C. §120, but had ata. Pursuant to 37 CDOCUMENTS ARE In the source of these documents.	n forms recited the application claims application claims we been edited to income TFR 1.98(d), NO COLENCLOSED. The present the present of th	oplication informates priority under licate the current applies OF THESE	pplication	
		, filed			
	Serial No.	, filed	;		

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the

Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1)	This In	formation Disclosure Statement is being filed:				
		within three months of the filing date of the patent application.				
		within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.				
	\boxtimes	before the mailing date of a first Office Action on the merits.				
		after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:				
	[the Statement under 37 CFR 1.97(e) (see "Statement" below);				
		or				
	[the Fee of \$180.00 set forth in 37 CFR 1.17(p); or				
	[No fee is owed by the applicants.				
		after the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).				
(2)	Stateme	ent				
		The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.				

(If this box is checked, do not check any further Statement boxes.) or The person signing immediately below hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement. The person making the statement is: the inventor(s) who sign(s) below: Signature of the Inventor(s) Typed or Printed Name of the Inventor(s) or a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below: Signature of the Person(s) Typed or Printed Name of the Person Address of Person Signing or the undersigned attorney who signs on the basis of the information: supplied by the inventor(s). supplied by an individual designated in 37 CFR 1.56(c). in the attorney's file.

Signature of the Attorney

(3)	Petition	Petition				
		Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. (This box checked only if a Final Office Action has issued)				
(4)	Fees					
	\boxtimes	No Fee is owed by the applicants.				
		The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.				
		The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.				
(5)	Method	Method of Payment of Fees				
		Attached is a check in the amount of \$240.00.				
		Charge Account No. 04-0480 in the amount of $$180.00$. (A duplicate of this request is attached).				
(6)	Authorization to Charge Additional Fees					
		If any additional fees are owed in connection with this communication, please charge Deposit Account No. 04-0480.				
(7)	Instructions as to Overpayment					
		Please credit Account No. 04-0480 for any overpayment.				
		Please refund Dechert Price & Rhoads in the amount of \$.				

ا سامور س A prompt and favorable response is earnestly solicited.

Respectfully submitted,

February 6, 2003

Arthur E. Jackson Registration No. 34,354

DECHERT LLP Princeton Pike Corporate Center PO Box 5218 Princeton, New Jersey 08543-5218

Fax: (609) 620-3259

Attn: Arthur E. Jackson, Esq.

(609 620-3254)

142064.1.07